By Karen Roman
Eliem Therapeutics, Inc. (Nasdaq: ELYM) said its new corporate name will be Climb Bio, Inc. and it will start trading at Nasdaq with the ticker symbol “CLYM” on Oct. 3.
This rebranding reflects Climb’s laser-focused mission on tackling immune-mediated diseases, it said in a statement.
Climb’s lead program is budoprutug (formerly TNT119), a potential disease-modifying treatment for autoantibody-driven diseases including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, it said.
“Since completing the Tenet Medicines acquisition, we have worked diligently to refocus the Company around a singular mission of developing treatments for patients with immune-mediated diseases,” said Dr. Aoife Brennan, CEO. “Our new name pays homage to the journey patients with autoimmune diseases must travel and to the work required to develop new treatments with them in mind.”
Contact:
